Triple-negative breast cancer is the most aggressive and lethal form of cancer due to lack of treatment options and high recurrence rates. The estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) are not expressed in these tumors. They are able to grow and spread faster than other types of cancer, therefore limiting treatment by chemotherapy. There are currently no targeted therapies developed for triple negative resurfacing at this time. We have previously reported on what we know about breast cancer biomarkers and targeting epigenetic proteins to prevent breast cancer.
In a recent study, researchers have identified estradiol as a new potential treatment for a subset of women with triple-negative breast cancer. The naturally occurring female hormone estradiol normally stimulates tumor expressing estrogen receptor alpha. Estrogen beta receptor has been shown to be present in 25% of triple-negative tumors and over 30% in estrogen receptor-positive tumors. Interestingly, estradiol inhibits the growth of triple-negative breast cancer tumors expressing estrogen receptor beta. Estradiol can bind to estrogen receptor beta and induce the secretion of cystatins that can inhibit tumor growth. Therefore, these findings suggest that estrogen receptor beta-targeted therapies could be a treatment option for the subset of women with estrogen receptor beta-expressing triple-negative breast cancer. Further clinical testing is needed to test the effectiveness against triple-negative cancer.
For more information:
http://www.pnas.org/content/early/2018/09/25/1807751115
Enzo Life Sciences provides a wide range of products for all your
Cancer research needs. We offer a highly sensitive
17β-Estradiol high sensitivity ELISA kit detecting as little as 14pg/ml of 17β-estradiol. Our
HER2/Neu monoclonal antibody provides a cost-effective opportunity for strong, clear staining with minimal background. Enzo’s
immunohistochemistry reagents provide a complete set of tools for an efficient IHC process from start to finish. Our
SCREEN-WELL® Cancer Library provides a unique collection of 275 compounds. Furthermore, our
FISH reagents provide everything you need for labeling, hybridization, and detection.